Total System Services, Inc. (NYSE:TSS) stock shows drops of -0.52% and traded at a price of $83.60 in preceding trading session.
TSYS (NYSE:TSS) reported that it continues to receive global recognition in 2018, as TSYS wasnamed by the Ethisphere Institute as one of the 2018 World’s Most Ethical Companies in the payment services category and also recently recognized by Thomson Reuters as one of the Top 100 Global Technology Leaders. TSYS is the only payments provider in the industry to be recognized by both of these prestigious organizations this year.
The Ethisphere Institute is a global leader in defining and advancing the standards of ethical business practices andnamed TSYS as one of its 2018 World’s Most Ethical Companies for the sixth time in the past seven years. This year, 135 honorees were recognized, spanning 23 countries and 57 industries. The twelfth class of honorees have record levels of involvement with their stakeholders and their communities around the world. Measuring and improving culture, leading authentically and committing to transparency, diversity and inclusion were all priorities for honorees.
In its inaugural year, Thomson Reuters selected TSYS as a top 100 global tech company based on its commitment to leadership across eight pillars of performance, such as: Financial, Management and Investor Confidence, People and Social Responsibility and Reputation. The top 100 companies identified are the tech industry’s most operationally sound and financially successful organizations, whose final scores across the pillars outshine more than 5,000 other technology companies around the world.
“These two prominent recognitions are a true testament to the dedication, hard-work and loyalty of our more than 11,800 team members around the globe,” said M. Troy Woods, Chairman, President and Chief Executive Officer, TSYS. “There are only a handful of recognizable brands named to both of these lists and for TSYS to be included, puts us in an exciting, unique position as we continue to make technological advances across our business, while serving our customers in an honest and transparent manner.”
Its 52-week range quite noticeable, lower range was $64.05% and hit highest level of $-7.03%. The overall volume in the last trading session was 7702 shares. The liquidity position of firm is on noticeable level, as its current ratio was calculated as 1.00 at the same time as its debt to equity ratio stands at 1.26.
Shares of Honeywell International Inc. (NYSE:HON) at the time when day-trade ended the stock finally inched down -0.05% to close at $149.40. Honeywell (NYSE:HON) disclosed that its UOP Russell business will provide a fractionation plant capable of producing 60,000 barrels per day of natural gas liquids (NGLs) to MarkWest Energy Partners. The company, which is a wholly owned subsidiary of MPLX LP (NYSE: MPLX), will install the plant at its Hopedale facility located in Jewett, Ohio.
The fractionation system will recover propane, isobutane, normal butane and pentane – or natural gasoline — from mixed natural gas liquids for use in petrochemical manufacturing.
“A growing number of gas processors are investing in NGL fractionation technology,” said Craig Ranta, Honeywell’s business director for UOP Russell. “Today, our fractionation technologies produce more than 850,000 barrels per day of natural gas liquids extracted from natural gas streams.”
Fractionation units are used to separate mixtures of extracted NGLs into individual pure components. The resulting products are used to manufacture a wide range of petrochemicals that are made into plastic resins, films and fibers, rubber, and fuel-blending components. The UOP Russell fractionation plant is customized for the large capacity requirements of MarkWest, and it represents an expansion of UOP Russell’s portfolio of pre-engineered fractionation products.
“In less than 40 weeks, Honeywell now can provide fractionation units for de-ethanizers up to 125,000 barrels per day and for depropanizers up to 60,000 barrels per day,” Ranta said. “This allows customers to get onstream and begin reliably generating revenue even faster than before.”
The volatility tends to amount of risk or uncertainty about size of changes in a security’s value; a higher volatility denotes that a security’s value can potentially be spread out over a larger range of values. The price volatility of HON was 3.21% for a week and 2.08% for a month as well as price volatility’s Average True Range for 14 days was 3.38. Shares price isolated negatively from its 50 days moving average with -3.98% and remote positively from 200 days moving average with 4.60%.
Advaxis, Inc. (NASDAQ:ADXS) makeup itself as poignant stock, knocked up 0.72% to trade at $2.79. Advaxis, Inc. (NASDAQ:ADXS) revealed that data from an earlier Phase 2 clinical study of axalimogenefilolisbac (ADXS11-001) as a treatment for persistent or recurrent metastatic (squamous or non-squamous cell) carcinoma of the cervix (PRmCC) was accepted for publication in the May edition of peer-reviewed International Journal of Gynecological Cancer. The article is titled, “A Randomized Phase 2 Study of ADXS11-001 Listeria monocytogenes-Listeriolysin O Immunotherapy With or Without Cisplatin in Treatment of Advanced Cervical Cancer.”
This multicenter, randomized Phase 2 study conducted in India compared axalimogenefilolisbac as a monotherapy with axalimogenefilolisbac in combination with chemotherapy (cisplatin) in 110 patients with PRmCC. The primary endpoint was overall survival (OS), and patients were followed every three months for up to 18 months for tumor response and survival status.
The most commonly reported treatment related adverse events were mild-to-moderate and related to cytokine release symptoms (chills, fever, vomiting and nausea), consistent with the observed safety profile in later clinical studies.
“These compelling results led to the conduct of the Phase 2 GOG-0265 study, where the 12-month OS rate with axalimogenefilolisbac was subsequently replicated in a more heavily-pretreated PRmCC population in the U.S. In addition, these data are supportive of our upcoming planned submission of a conditional Marketing Authorization Application with the European Medicines Agency for axalimogenefilolisbac for the treatment for metastatic cervical cancer, and give us added confidence in our immunotherapy as a treatment for these patients with limited treatment options,” stated Anthony Lombardo, interim Chief Executive Officer of Advaxis.
The firm holds total outstanding shares are 42.17 million shares and floated shares were 36.53 million. As the returns are concern, return on equity was recorded -114.00% and firm decreased its return on investment -173.30% while its return on asset stayed at -75.60%.